Seeking Alpha

Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than...

Optimer Pharmaceuticals (OPTR) trades lower in the post-session after reporting a wider than expected Q3 loss. SG&A expenses jumped fourfold Y/Y to $26.9M, compared to $4.8M for the prior year, primarily due to its infrastructure build-up and marketing expenses related to the launch of its blockbuster drug DIFICID. Shares -7.8% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)